- Home
- HKD vs AVIR Comparison
HKD vs AVIR Comparison
Compare HKD & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HKD | AVIR |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.7M | 434.5M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HKD | AVIR |
|---|---|---|
| Price | $1.69 | $4.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 192.4K | ★ 287.6K |
| Earning Date | 02-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $2.78 |
| 52 Week High | $5.47 | $6.45 |
Technical Indicators
Market Signals| Indicator | HKD | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 34.78 |
| Support Level | $1.59 | $3.27 |
| Resistance Level | $1.69 | $4.80 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 40.00 | 21.23 |
Price Performance
Historical ComparisonAbout HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment; hotel operations, hospitality and VIP services segment; media and entertainment services segment; and Strategic investments. The company generates maximum revenue from Digital solutions services segment, which provides its institutional and corporate clients with exclusive, paid access to enhance their investor communication, investor relations and corporate communication to potentially maximize their valuation, as well as providing digital solution services. Geographically, the company generates revenue from China, Hong Kong, Europe, Americas and Southeast Asia.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.